Perimenopause hormone therapy on TikTok: what's real?

What did @elevatemd actually say?

In a 416K-view TikTok, a creator identified as a medical professional gave perimenopausal women a ranked breakdown of hormone therapy delivery methods. The short version: synthetic hormones are dangerous, bioidentical hormones are "the holy grail," pellets are "barbaric" and inconsistent, and injectable hormones are the clear winner because they're the "most bioavailable" with the "least amount of side effects." The video also claims transdermals have "very inconsistent absorption" and don't show up accurately on bloodwork.

That's a lot of confident ranking for a topic where the clinical literature is genuinely complicated. Some of what they said is defensible. Some of it is a sales pitch dressed up as education.

Does the science back this up?

Partially, but the framing does real damage to nuance. The bioidentical versus synthetic distinction, as presented here, is the biggest problem. The claim that synthetic hormones carry "the highest cancer and clotting risk" while bioidenticals are categorically safer is not how the evidence actually reads.

The Women's Health Initiative, which is the study most people are referencing when they discuss HRT cancer risk, used conjugated equine estrogens and medroxyprogesterone acetate, both synthetic. But the risk elevation for breast cancer was modest, confined largely to the combined estrogen-progestin arm, and was not replicated in the estrogen-only arm for women without a uterus (Rossouw et al., 2002, JAMA). More recent analyses, including Manson et al. (2017, JAMA), have substantially revised the picture downward. Meanwhile, micronized progesterone, which is bioidentical, does appear to carry a lower breast cancer risk than synthetic progestins (Fournier et al., 2008, Breast Cancer Research and Treatment). So the creator is gesturing at a real distinction, but flattening it into "synthetic bad, bioidentical holy grail" misrepresents the actual science.

On pellets specifically, the criticism about dose inflexibility is accurate. A 2019 review by Glaser and Dimitrakakis in Maturitas noted that pellet dosing is fixed post-insertion, which is a genuine clinical limitation. The "massive rush" claim is less well-documented as a universal effect.

What did they get wrong (or right)?

They got the pellet inflexibility point right. Once a pellet is inserted, you cannot adjust the dose. That is a real limitation that many pellet-enthusiast providers underemphasize, and it deserves to be said plainly.

The oral hormone critique is also defensible. Oral estrogen undergoes first-pass hepatic metabolism, which does increase triglycerides and clotting factor production compared to transdermal routes. This is well-established in the literature (Straczek et al., 2005, Stroke).

What they got wrong is the binary "bioidentical equals safer" framework. The FDA does not recognize the marketing term "bioidentical" as a safety classification. Compounded bioidentical hormones in particular are not FDA-approved and lack the clinical trial data that regulated formulations carry. Calling them "the holy grail" without that caveat is misleading to a lay audience.

The transdermal bloodwork claim, that "transdermal hormones do not always accurately reflect on your blood work," is partially true for testosterone gels but is an oversimplification. Serum estradiol levels from patches are measurable and routinely used in clinical monitoring. The claim, as stated, overgeneralizes.

What should you actually know?

The delivery method conversation matters, but it should not be happening in isolation from a patient's individual risk profile, symptom burden, and clinical history. No single delivery method is universally best. The Menopause Society (formerly NAMS) guidelines do not rank injectables above all other forms. They emphasize individualization.

Injectable estradiol and testosterone are legitimate clinical tools. For testosterone specifically in women, injectable testosterone cypionate or enanthate can be dosed and titrated with reasonable precision, and some clinicians do prefer this for that reason. But "most bioavailable with the least side effects" is a marketing claim, not a citation.

If you are in perimenopause and considering HRT, the most useful thing you can do is find a provider who will assess your lipid panel, cardiovascular risk, personal and family cancer history, and symptom profile before recommending any delivery method. A TikTok video ranking delivery methods from worst to best, ending with a pitch for the method the creator apparently offers, is a starting point for questions, not a clinical recommendation.